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Background: Hepatitis C virus (HCV) infection was recently recognized as an independent risk factor for insulin
resistance (IR), the onset phase of type 2 diabetes mellitus (T2DM). Phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) negatively regulates PI3K/Akt signaling pathway, which is critical for IR development and
progression of cirrhosis to hepatocellular carcinoma (HCC). Here, we investigate the role of PTEN in HCV-associated
IR and explored the mechanisms by which HCV regulates PTEN.
Methods: Western blotting was used to detect the levels of insulin signaling pathway components, including
insulin receptor substrate-1 (IRS-1), phosphorylated IRS-1 (pIRS-1) at serine 307 (Ser307), both phosphorylated
Akt (pAkt) and total Akt. A time-course experiment measuring activation of the insulin signaling pathway was
performed to assess the effect of HCV infection on insulin sensitivity by examining the phosphorylation levels of Akt
and GSK3β, a downstream target of Akt. Huh7.5.1 cells were transduced with a lentiviral vector expressing PTEN or
PTEN shRNA, and IRS-1 and pIRS-1 (Ser307) levels were determined in both HCV-infected and uninfected cells. The
pc-JFH1-core plasmid was constructed to explore the underlying mechanisms by which HCV regulated PTEN and
therefore IRS-1 levels.
Results: HCV infection inhibited the insulin signaling pathway by reducing the levels of IRS-1 and pAkt/Akt while
increasing phosphorylation of IRS-1 Ser307. In addition, HCV infection decreased the sensitivity to insulin-induced
stimulation by inhibiting Akt and GSK3β phosphorylation. Furthermore, PTEN mRNA and protein levels were
reduced upon HCV infection as well as transfection with the pc-JFH1-core plasmid. The reduction in IRS-1 level
observed in HCV-infected cells was rescued to a limited extent by overexpression of PTEN, which in turn slightly
reduced pIRS-1 (Ser307) level. In contrast, IRS-1 level were significantly decreased and phosphorylation of IRS-1 at
Ser-307 was strongly enhanced by PTEN knockdown, suggesting that both reduction in IRS-1 level and increase in
IRS-1 phosphorylation at Ser307 upon HCV infection occurred in a PTEN-dependent manner.
Conclusions: HCV infection suppresses the insulin signaling pathway and promotes IR by repressing PTEN,
subsequently leading to decreased levels of IRS-1 and increased levels of pIRS-1 at Ser307. The findings provide
new insight on the mechanism of HCV-associated IR.
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Figure 1 Effect of HCV infection on the insulin signaling
pathway. Equal amounts of cellular lysates from uninfected and
HCV-infected Huh7.5.1 cells at a M.O.I of 2 for 48 h were subjected
to western blot analysis using anti-pIRS-1Ser307, IRS-1, pAkt, Akt, and
core-specific antibodies. Anti-GAPDH antibody was used as an
internal control to verify protein loading.
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HCV infection is prevalent in 1–3% of the global popu-
lation and is a primary cause of liver diseases such as
chronic hepatitis, steatosis, cirrhosis, and hepatocellular
carcinoma (HCC) [1,2]. Chronic HCV infection is also
associated with a multifaceted disorder correlating with
various metabolic disorders, including insulin resistance
(IR), type 2 diabetes mellitus (T2DM), lipid metabolism,
obesity and liver steatosis [2,3]. IR is a systemic pre-
diabetic disorder wherein an increased level of insulin
needs to maintain normal glucose levels in peripheral
tissues, especially in muscle and adipose tissue [4]. Pre-
vious studies have shown that IR is the major factor
leading to hepatic steatosis and fibrosis, weakened host
immune response to viral infection, and is involved in
the development of HCC [5-7].
Recently, more studies have revealed that HCV infec-
tion appears to interfere with glucose homeostasis and
ultimately induce T2DM [8]. Signaling events triggered
by insulin stimulation are involved in the molecular
mechanisms of IR. Binding of insulin to its receptor
phosphorylates insulin receptor substrate 1/2 (IRS-1/2),
which in turn activates the PI3K/Akt signaling pathway
and ultimately leads to an increase in glucose uptake
and glycogen synthesis [9]. Although the precise me-
chanisms underlying HCV-mediated IR remain poorly
understood, several hypotheses have been proposed.
During HCV infection, tumor necrosis factor (TNF)-α
system is activated and interleukin-6 levels are increased,
which disturb tyrosine phosphorylation of IRS-1. Sup-
pressor of cytokine signaling-3 (SOCS-3) level was sub-
sequently increased to promote proteasomal degradation
of IRS-1/2. Moreover, HCV infection eventually leads to
liver steatosis and fibrosis, increased oxidative stress and
peroxidation, all of which trigger a cascade of inflamma-
tory responses, thus contributing to the development of
IR [9-11].
Phosphatase and tensin homolog deleted on chromo-
some 10 (PTEN) is first identified as a tumor suppressor
that dephosphorylates both proteins and phosphoino-
sitides [12]. However, whether PTEN plays a role in
regulation of the insulin signaling pathway remains to be
clarified. Vinciguerra M et al. showed that PTEN dele-
tion of liver tissue led to enhanced peripheral glucose
metabolism in mice [13]. Hypersensitivity to insulin of
the results was consistent with the fact that PTEN might
negatively regulate peripheral insulin sensitivity. Para-
doxically, they also found that free fatty acid-mediated
PTEN down-regulation caused resistance to some of the
insulin metabolic effects in hepatoma HepG2 cells by
decreasing phosphorylation of insulin receptors and sub-
sequent IRS-1 expression [14]. Therefore, further studies
are needed to clarify whether PTEN down-regulation in
HCV-infected hepatocytes is also a causal factor for IR.To determine whether alterations in PTEN expression/
activity in human hepatocytes were implicated in the
development of IR during HCV infection, we inves-
tigated its expression pattern in HCV-infected cells and
its impact on the modulation of IRS-1. We found that
HCV infection down-regulates PTEN expression and
conversely increases phosphorylation of IRS-1 at Ser307,
which subsequently impairs the PI3K/Akt signaling
pathway, leading to IR. These results provide new in-
sights into the mechanisms of HCV-associated IR.
Results
HCV infection inhibits the insulin signaling pathway
IRS-1, an adaptor protein for the insulin signaling pathway,
undergoes proteasomal degradation and post-translational
modification to arrive at a balance between its Tyr/Ser
phosphorylation [3,4]. To determine the status of the insu-
lin signaling pathway in HCV-infected cells, we examined
the levels of IRS-1 and its Ser307-phosphorylated form in
Huh7.5.1 cells infected with JFH1-based HCVcc. The
phosphorylation of IRS-1 at Ser307 was remarkably in-
creased, and both IRS-1 protein and pAkt/Akt levels were
decreased (Figure 1), indicating that the PI3K/Akt signal-
ing pathway was also attenuated in the course of HCV in-
fection. These results suggest that HCV infection impairs
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and therefore PI3K/Akt signaling pathway.
HCV infection decreases sensitivity of Huh7.5.1 cells to
exogenous insulin
Activated Akt can induce phosphorylation of glycogen
synthase kinase 3β (GSK3β), a key component of glyco-
gen synthesis, at the serine residues and thus inactivate
its kinase activity, which leads to glycogen production by
activation of glycogen synthase [15]. To assess the effect
of HCV infection on insulin sensitivity, we examined the
phosphorylation status of Akt and GSK3β induced by
insulin stimulation. We performed a time-course expe-
riment in uninfected Huh7.5.1 cells, which showed that
phosphorylation of Akt at Ser473 and GSK3β at Ser9
reached a maximum level at 30 min after stimulation
with 100 nM insulin. Conversely, infected cells that
were stimulated with the same concentration of insulin
showed attenuated phosphorylation of Akt and GSK3β
at the same serine residues. These results showed that
HCV 2a induced insulin sensitivity by decreasing phos-
phorylation of Akt at Ser473 and GSK3β at Ser9.
Down-regulation of IRS-1 and up-regulation of pIRS-1 at
Ser307 upon HCV 2a infection is PTEN-dependent
Because the PI3K/Akt signaling is involved in HCV-
mediated IR, we next evaluated whether its negative
regulator PTEN also altered its expression pattern dur-
ing HCV infection. To elucidate this possibility, we de-
tected PTEN expression in HCVcc-infected Huh7.5.1
cells at different multiplicity of infection (M.O.I) for
48 h by western blotting and real-time PCR (Figure 2).
Compared with uninfected cells, HCV-infected cells
showed a significant reduction in PTEN protein and
mRNA expression levels (Figure 3a,b).
To further explore the impact of PTEN expression on
the key effector IRS-1 that mediates IR during HCV in-
fection, we examined pIRS-1 and IRS-1 levels in HCV-
infected cells in which PTEN was either overexpressed
or knocked down by the lentivirus. Compared to IRS-1
expression upon HCV infection in Huh7.5.1 cells and
empty vector group, IRS-1 levels were partially rescued,
and pIRS-1 levels were slightly reduced by PTEN over-
expression regardless of JFH1-based HCVcc infection
(Figure 3c). In contrast, IRS-1 levels were obviously de-
creased simply due to the depletion of PTEN (lanes 3 vs.
5 and lanes 4 vs. 6 in Figure 3d). This result suggested
that pIRS-1 Ser307 might be another direct phosphory-
lational substrate for PTEN, since Yuji Shi et al. have
demonstrated that PTEN is a protein tyrosine phospha-
tase for IRS-1 [16]. Moreover, phosphorylation of IRS-1
at Ser307 was considerably enhanced by PTEN knock-
down, especially in the infected cells. Taken together,
these data demonstrate that down-regulation of IRS-1and increase of pIRS-1 at Ser307 upon HCV 2a infection
occurs in a PTEN-dependent manner.
HCV infection down-regulates PTEN expression via HCV
core protein
To elucidate the underlying mechanism by which HCV
regulated PTEN and subsequent IRS-1 levels, Huh7.5.1
cells were transfected with one of the following plas-
mids: pc-JFH1-core expressing the HCV core protein
from the strain JFH1 or pcDNA3.1 as the negative con-
trol (Figure 4). Our results showed that both PTEN and
IRS-1 expression decreased, while IRS-1 Ser307 phos-
phorylation increased in the HCV core-transfected cells.
These results indicate that HCV 2a core protein alone ap-
pears to be sufficient for repression of PTEN and IRS-1,
as well as promotion of pIRS-1 at Ser307 in the insulin
signaling pathway, which are molecular events linked
with IR.
Discussion
Our results demonstrate that HCV 2a infection inter-
feres with the function of IRS-1 via down-regulation of
PTEN expression and increase in phosphorylation of
IRS-1 at Ser307 inHuh7.5.1 cells. This study uncovered
a sequential event in which HCV regulates several criti-
cal insulin signaling molecules during its early infection,
which partially contributes to the mechanical elucidation
of HCV-associated IR.
Recently, chronic HCV infection has been regarded as
an independent risk factor in the incidence of T2DM.
Compared to HBV infection, the incidence of T2DM is
approximately 1.8 to 2.5-fold higher in patients with
chronic HCV infection. In such infected patients with
no or minimal liver fibrosis, IR is the major factor that
contributes to the occurrence of T2DM [17]. Therefore,
there is a clinically relevant need to understand the ex-
plicit relationship between HCV infection and IR as well
as the underlying mechanisms by which HCV perturbs
insulin signaling pathway. On the basis of our study, we
speculated that establishment of abnormal insulin sig-
naling by HCV 2a should be the initial step that even-
tually leads to the HCV-associated IR.
PI3K/Akt signaling pathway is pivotal to the complex
network of insulin signaling pathways. Activation of PI3K/
Akt is a critical step to ensure subsequent phosphorylation
of GSK3β and activation of glycogen synthase involved in
insulin metabolic effects [15]. Association of insulin re-
ceptors with the IRS-1 adaptor protein upon insulin
stimulation leads to phosphorylation and activation of
downstream PI3K/Akt, and eventually promotes synthesis
of glycogen and fatty acids to maintain normal blood
glucose levels [18]. Our results suggest that HCV infec-
tion inhibits insulin-induced phosphorylation of Akt at
Ser473 and subsequent phosphorylation of GSK3β
Figure 2 Effect of HCV infection on insulin-induced phosphorylation of Akt and GSK3β. Huh7.5.1 cells were seeded in a 24-well plate and
subjected to serum-free incubation for 20 h, followed by insulin stimulation for the indicated time (0, 15, 30, and 60 min). Western blotting with
indicated antibodies revealed a time-dependent change in the phosphorylation of Akt (a) and GSK3β (b). Furthermore, Huh7.5.1 cells and
HCV-infected cells were stimulated with 100 nM insulin for 30 min or left untreated. Extracted proteins were analyzed with antibodies against
pAkt, Akt, pGSK3β, and GSK3β (c).
Figure 3 Effect of HCV infection on PTEN expression in Huh7.5.1 cells. Huh7.5.1 cells were routinely infected with different M.O.I of HCV 2a
cc for 48 h and equal amounts of cellular lysates were subjected to western blotting for evaluating PTEN protein level (a) and qRT-PCR for PTEN
mRNA expression (b). Huh7.5.1 cells, empty lentivector groups, and PTEN or PTEN shRNA expressing cells were infected with HCV viral particles
(M.O.I = 2). Representative immunoblots of pIRS-1Ser307, IRS-1, PTEN and GAPDH expression in cells showing PTEN overexpression (c) and downregulation
(d), respectively.
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Figure 4 Effect of transfection of Huh7.5.1 cells with JFH1-core
plasmid on PTEN expression. Huh7.5.1 cells transfected with
empty vector or core expression vector were subjected to western
blotting for pIRS1Ser307, IRS-1, PTEN and HCV core-specific antibodies.
GAPDH was used as an internal control to verify protein loading in
each well.
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to insulin results from the suppression of glucose uptake
as well as glycogen synthesis. A previous study found in-
stead that inhibition of phosphorylation at Thr-308 on
Akt was more important than that at Ser473 for reduced
insulin-stimulated glucose transport. This was thought to
be due to the fact that phosphorylation of Akt at Ser473
appeared to precede phosphorylation by phosphoinositide
dependent kinase-1 (PDK1) at Thr-308 [19]. Since we did
not address phosphorylation of Akt at Thr308 in the
present report, we cannot comment on its importance but
can say definitively that impaired Ser473 phosphorylation
is involved in reduced sensitivity to insulin during HCV
infection.
Moreover, previous studies have indicated that HCV
infection interferes with the insulin signaling cascade to
promote IRS-1 and IRS-2 proteasomal degradation, by
inducing the expression of SOCS3 and proinflammatory
cytokines [10]. For example, the induction of TNF-α
causes phosphorylation of IRS-1 at Ser312 and impedes
insulin signaling, especially in HCV patients with more
severe liver disorders [9,20]. It appears that different
pathways targeted by different HCV genotypes perturb the
normal insulin signaling pathway. In HCV 3a, HCV core
protein promotes IRS-1 degradation via up-regulatingsuppressors of cytokine signaling 7 (SOCS7) and down-
regulating peroxisome proliferator-activated receptor
gamma (PPAR-γ). HCV 1b core protein impedes IRS-1
signaling through activation of the mammalian target of
rapamycin (mTOR) activity [21]. A recent study suggested
that HCV 2a suppresses IRS-1 function by activating the
mTOR/S6K1 signaling pathway. It also perturbs glucose
metabolism by down-regulating the glucose transporter
type 4 (GLUT4) as well as up-regulating phosphoenol-
pyruvate carboxykinase 2 (PCK2) to promote IR [22,23].
It has been demonstrated that phosphorylation of IRS-1
at Ser1101 in the mTOR/S6K1 pathway makes IRS-1
releasing from intracellular complexes, leading to its deg-
radation [24]. Likewise, in HCV-NS5A-expressing hepa-
toma cells, increased phosphorylation of IRS-1 at Ser307
was shown to be involved in enhanced gluconeogenic and
lipogenic gene expression, thereby hampering metabolic
activity and contributing to IR [25]. Therefore, phosphor-
ylation of IRS-1 at Ser307 was further examined in our
study, and we observed a similar increase of pIRS-1 at
Ser307 with HCV 2a infection and core protein trans-
fection (Figures 1 and 4). Our data further verifies that the
increased pIRS-1 at Ser307 contributes to HCV-mediated
IR.
As a negative regulator of the PI3K/Akt pathway, PTEN
antagonizes insulin-dependent cell signaling, where its
down-regulation improves insulin sensitivity. Del Campo
et al. have suggested that HCV infection modifies the in-
sulin signaling pathway by down-regulation of PTEN pro-
tein expression via post-transcriptional regulation events,
especially in the presence of insulin [26]. Our results
showed that HCV infection and core protein transfection
down-regulated PTEN at both the protein and mRNA
level. The data are somehow discrepant with those of a
previous study wherein HCV 3a core protein triggered
down-regulation of PTEN by interrupting its mRNA
translation in a 3′-UTR-dependent manner [26,27]. The
discrepancy between the two studies may due to different
HCV genotypes. In addition, we also demonstrated that
depletion of PTEN accelerated degradation of IRS-1 and
promoted Ser307 phosphorylation of IRS-1, indicating
that the balance between IRS-1 and pIRS-1 at Ser307 was
PTEN-dependent.
Our results have revealed a central role for PTEN
down-regulation in mediating the incidence of IR in
HCV 2a-infected or pc-JFH-1-core plasmid transfected
hepatocytes. The findings of our study support the re-
cent view that alternation of PTEN expression/activity
plays a crucial role in metabolic disorders of the liver
[28]. Even Vinciguerra M et al. have suggested that liver-
specific PTEN knockout mice were hypersensitive to
insulin in spite of the development of steatosis and stea-
tohepatitis [13], the role of PTEN in hepatic steatosis
with IR, which is more common in HCV infection than
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matter of debate.
Previous studies have suggested that IR in patients
with chronic hepatitis C accelerates the process of liver
disease and impaired sustained virological response to
the standard therapy of peginterferon and ribavirin [7].
Thus, dysregulated PTEN expression caused by HCV in-
fection may affect hepatic insulin sensitivity, but may
also lead to progression to severe liver malignancies, of
which PTEN is frequently mutated or deleted. Moreover,
microRNAs, particularly miR-21, down-regulate PTEN
to promote hepatocyte proliferation and invasiveness
[29]. Indeed, strategies aimed to restore PTEN expres-
sion/activity with inhibition of IKK/NF-κB and mTOR
signaling in injured hepatocytes might counteract hep-
atic IR, steatohepatitis and potentially more serious liver
diseases for prolonged survival [14,30]. Recent studies by
Serfaty L et al. have suggested that for the development
of direct-acting antivirals (DAAs) such as telaprevir for
administration to patients with chronic HCV genotype 1
infection, baseline Homeostasis Model Assessment on
IR (HOMA-IR) was not a predictor for the achievement
of sustained virological response (SVR) [31]. Never-
theless, DAA-based therapy is expensive and associated
with many side effects. As long as peg-IFN/RBV is the
standard therapy for chronic HCV infection, IR in HCV
infection is worth noting. The detailed mechanisms by
which HCV infection modifies the function of PTEN
and the role of PTEN in the pathogenesis of HCV-
associated IR and T2DM should be explored further.
Taken together, our results show that HCV infection
triggers IR in a PTEN-dependent manner. The role of
PTEN in HCV-associated IR is to promote the phos-
phorylation of IRS-1 at Ser307, resulting in the inhibi-
tion of the function of IRS-1. The findings provide new
insight into the mechanisms of HCV-associated IR.
Materials and methods
Antibodies and reagents
Insulin and antibodies against IRS-1, pIRS-1 (Ser307),
PTEN, Akt, pAkt (Ser473), GSK3β and pGSK3β (Ser9)
were purchased from Beyotime, China. GAPDH anti-
body was from Abmart, Shanghai. HCV core mono-
clonal antibody was obtained from Abcam. Horseradish
peroxidase (HRP)-conjugated secondary antibodies were
from Santa Cruz Biotechnology.
Cell culture
Human hepatoma Huh7.5.1 cells (kindly provided by
Dr.Jing Zhong from Institute Pasteur of Shanghai, Chinese
Academy of Sciences, Shanghai, China) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco
BRL, USA) with 10% (v/v) fetal bovine serum (FBS)
(Gibco) and 1 mM glutamine, 1% penicillin/streptomycin,100 nM nonessential amino acids (NEAA) at 37°C in
5% CO2.
Production of HCVcc genotype 2a (clone JFH1) and
infectivity assays
The plasmid pJFH-1, as the temple for HCVcc generation,
was kindly provided by T. Wakita (National Institute of
Infectious Disease, Japan). Briefly, the pJFH-1 plasmid was
linearized, transcribed with the MEGAscript T7 kit
(Ambion, Austin, USA) in vitro and then delivered into
Huh-7.5.1 cells by electroporation. Supernatants collected
at 4 to 5 days post-transfection were centrifuged at
1000 rpm for 5 minutes and filtered through a 0.45 μm-
pore-size cellulose acetate membrane (Nalgene, Rochester,
NY). Virus particles were stored at −80°C.
At 2 days post infection, Huh7.5.1 cells were fixed and
permeabilized with methanol, and then immunostained
with serum from HCV patients. HCV-JFH1 titers were
determined from cell culture supernatant by fluorescent
focus-forming assay. The virus titer was calculated as
focus-forming units/ml. In our study, the multiplicity of
infection (M.O.I) for infection of hepatocytes was 1–2.
Plasmid construction and transfection
The core coding regions of pJFH-1 plasmid were am-






The fragment was subsequently subcloned into vector
pcDNA3.1. The resulting constructs, the pc-JFH1-core
plasmid was verified by sequencing and transiently tran-
sfected into Huh7.5.1 cells according to Lipofectamine
2000 (Inviteogen, Carlabsd, CA) instructions.
Lentivirus of PTEN production
The human PTEN coding sequence was cloned into
pRRLsin.PPTs.hCMV.GFPpre by PCR to generate pLenti-





Then HEK 293 T cells were transient transfected with
plasmid pLenti-PTEN, MDL, REV and VSVG to produce
recombinant lentiviral particles. The supernatants were
collected at 48 hours after transfection and then cen-
trifugated at 3000 rpm for 5 min to remove cellular
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filtered through 0.45 μm pore-sized PVDF membranes
and viral titers were calculated by quantitative realtime-
PCR. Cells transducted with Lenti-EGFP were used as
controls
To knockdown PTEN, we purchased GV248-shPTEN
(short hairpin RNAs) targeting the following sequence
5’- ACAGCTAGAACTTATCAAA-3’ from Ji Kai Gene
and verified by Western blot.
Western blot assay
Cells were lysed with 0.1% SDS RIPA buffer (20 mM Tris–
HCl, 250 mM NaCl, 3 mM EDTA, 10% glycerol (v/v))
(Beyotime) containing protease inhibitors and phosphates
inhibitors on ice. Extracted proteins were quantitated by
Bradford method (Beyotime) and then separated by
SDS-PAGE (12.5% acrylaminde). Afterwards, proteins
were transferred onto PVDF membranes (Millipore) and
blocked in 5% non-fat milk for 2 h, and then incubated
with primary antibodies overnight at 4°C, followed by the
corresponding HRP-conjugated secondary antibodies for
1 h. The blots were finally detected by the enhanced che-
miluminescence on Gene Gnome HR image capture
(Cambridge, UK) and analyzed by GeneTools software.
The primary antibodies used were anti-IRS-1, Akt, pAkt,
PTEN, GSK3β, pGSK3β antibodies (1:500), HCV core
(1:1000) and GAPDH antibody (1:2000).
Reverse transcription and real-time PCR
Total cellular RNA was extracted by Trizol Reagent
(Invitrogen) as instructions. 1 μg of total cellular RNA to
cDNA synthesis was performed by M-MLV reverse tran-
scriptase (Progema) with random hexamers. For the
quantification of PTEN, semi-quantitative real-time PCR
was performed with normalization for GAPDH using
Uiversal SYBR Green Master (Takara) on a Rotor-Gene
3000 real-time thermal cycler (Corbett, Sydney, Australia).





All experiments were carried out in triplicate on a Ste-
pOne Plus real-time PCR system (Applied Biosystems)
and the data was analyzed by SDS v2.3 software.
Statistical analysis
Results were presented as mean ± standard deviation
(SD) and analyzed by One-Way ANOVA test using SPSS
software19.0. P <0.05 was considered statistically sig-
nificant. All above experiments were performed at least
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